Monitor upcoming quarterly results for confirmation of the 17-20% revenue growth guidance and progress toward positive GAAP net income. The high specification rate in clinical trials (>70%) provides a long-term revenue visibility moat, but near-term execution on multi-product penetration and margin expansion will determine stock trajectory.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 3 $27.25entry
- T+1 · 6mo ago −0.59%α −0.99% · $27.09
- T+5 · 5mo ago −2.17%α +1.65% · $26.66
- T+20 · 5mo ago +3.16%α +4.16% · $28.11
- T+60 · 3mo ago +36.51%α +34.02% · $37.20
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioLife Solutions filed an 8-K furnishing an investor presentation for the Jefferies Global Healthcare Conference. The presentation highlights FY2025 revenue of $96M (29% organic growth), 26% adjusted EBITDA margin, and provides 17-20% revenue growth guidance for FY2026, with expectations of positive GAAP net income for the full year. The filing is a routine investor relations update with no new material financial disclosures beyond previously reported figures.
Key Facts
- FY2025 revenue of $96M with 29% organic growth
- FY2025 adjusted EBITDA margin of 26%
- FY2025 gross margin of 65%
- 17-20% revenue growth guidance for FY2026
- Expects positive GAAP net income for FY2026
- Q1 2026 revenue of $27.5M
- Products specified in >70% of cell-based therapy clinical trials and ~90% of commercially relevant FDA-approved cell-based therapies
- Net cash balance of $114M as of FY2025
- Investor presentation furnished as EX-99.1 for use at Jefferies Global Healthcare Conference
Financial Impact
FY2025 revenue $96M, 29% organic growth; FY2026 revenue growth guidance 17-20%; Q1 2026 revenue $27.5M
Risk Factors
- Cell therapy market growth may not materialize as forecast
- Customer concentration risk with large biopharma partners
- Execution risk on multi-product penetration and margin expansion
- Potential competitive displacement in biopreservation media
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-040048 |
| Document: blfs-20260603.htm | 0001628280-26-040048 |
| Document: 0001628280-26-040048-index-headers.html | 0001628280-26-040048 |
| Document: 0001628280-26-040048-index.html | 0001628280-26-040048 |
| Document: 0001628280-26-040048.txt | 0001628280-26-040048 |
Track record
15 reports on BLFS
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry price pending
- Nov 6, 202610d ago Institutional Cluster Bearish 4/10 No price data
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 No price data
- Oct 16, 20264w ago 15-12G Neutral 4/10 No price data
- Oct 13, 20264w ago EFFECT Neutral 3/10 No price data
- Oct 13, 20264w ago EFFECT Neutral 3/10 No price data
- Oct 6, 20265w ago 8-K Bullish 7/10 Entry $39.00 No price data
- Sep 30, 20266w ago 425 Neutral 4/10 Entry $38.85 No price data
- Sep 30, 20266w ago DEFA14A Neutral 4/10 Entry $38.85 No price data
- Sep 24, 20267w ago SC 13G Neutral 4/10 Entry $38.58 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers